Allakos says experimental skin disease drug fails mid-stage studies
16/01/2024 12:17
Jan 16 (Reuters) - Allakos Inc ALLK.O said on Tuesday
that it plans to discontinue studies testing its experimental
skin disease drug after it failed two mid-stage studies.
The company also said it plans to cut 50% of its workforce
as part of a restructuring.
(Reporting by Sneha S K; Editing by Sonia Cheema)
((Sneha.SK@thomsonreuters.com;))
Recent news on Allakos
See all newsAllakos Inc reports results for the quarter ended March 31 - Earnings Summary
Allakos Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-M-tron, Rocket Companies, TKO Group
Allakos soars on buyout deal with Concentra Biosciences
Brief: Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences